Connect with us


Sandbagging an Alzheimer’s Treatment – WSJ



#Sandbagging #Alzheimers #Remedy #WSJ

The Meals and Drug Administration evaluates medication for security and efficacy, however now the Facilities for Medicare and Medicaid Providers needs to behave as a political verify on the FDA’s choices. Final week CMS refused to cowl a novel Alzheimer’s therapy for hundreds of thousands of sufferers as a result of it disagreed with FDA approval.

Biogen ’s Aduhelm is the primary FDA-approved therapy proven to sluggish the development of Alzheimer’s. However the drug is now ensnared in a political battle. The general public-health left thinks FDA is approving too many new costly medication with marginal advantages, and it needs CMS to overrule the drug company. Progressives are cheering CMS’s Aduhelm determination as a precedent that the company can prohibit entry to new FDA-approved remedies. Aduhelm is the goal right now, however most cancers and gene therapies may very well be subsequent.